Investing in healthcare companies can be a beneficial approach, especially for those seeking opportunities with substantial yields. With the global population continuously aging and the demand for healthcare services on the rise, businesses within this industry are positioned for expansion. Two notable companies in this respect are AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY). Both possess solid market standing and offer attractive dividends.

AbbVie Inc., widely recognized for its leading medication Humira, is consistently broadening its portfolio through strategic acquisitions and the introduction of new products. The company’s calculated growth approach has allowed it to sustain a competitive advantage in the pharmaceutical sector. Given its dependable dividend yield, AbbVie remains an appealing choice for investors prioritizing income.

Similarly, Bristol-Myers Squibb has cemented its reputation as a pioneer in developing innovative therapies. Its recent acquisition of Celgene has expanded its range of products and enhanced its research and development capabilities. The company’s robust financial performance and dedication to delivering shareholder value make it a sound option for individuals looking to invest in the healthcare industry.

Both AbbVie and Bristol-Myers Squibb not only present investors with the potential for appreciation in capital but also provide appealing dividend yields, making them suitable for long-term investment portfolios. As the healthcare landscape continues to evolve, these corporations are well-equipped to capitalize on the increasing need for advanced treatments and medications.

Footnotes:

• AbbVie Inc. is known for its blockbuster drug Humira. .
• Bristol-Myers Squibb recently acquired Celgene to enhance its product line. .